{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T04:01:07Z","timestamp":1749355267611,"version":"3.41.0"},"reference-count":49,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,6,1]]},"DOI":"10.2169\/internalmedicine.4456-24","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T22:14:20Z","timestamp":1730412860000},"page":"1612-1622","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Ipragliflozin on Skeletal Muscle Adiposity in Patients with Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease"],"prefix":"10.2169","volume":"64","author":[{"given":"Yuko","family":"Ishimaru","sequence":"first","affiliation":[{"name":"Clinical Research Center, Saga University Hospital, Faculty of Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaomi","family":"Kessoku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Japan"},{"name":"Department of Palliative Medicine, International University Health and Welfare Narita Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, International University Health and Welfare School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Kitajima","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Japan"},{"name":"Department of Clinical Gastroenterology, Eguchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Hyogo","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Japan"},{"name":"Hyogo Life Care Clinic Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Sapporo Kosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shin-yurigaoka General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Kubotsu","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Isoda","sequence":"additional","affiliation":[{"name":"Liver Center, Saga University Hospital, Faculty of Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miwa","family":"Kawanaka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, Kawasaki Medical Center, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Anzai","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoji","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Biostatistics Center, Kurume University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Education and Research Center for Community Medicine, Faculty of Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Japan"},{"name":"Liver Center, Saga University Hospital, Faculty of Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78: 1966-1986, 2023.","DOI":"10.1097\/HEP.0000000000000520"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69: 2672-2682, 2019.","DOI":"10.1002\/hep.30251"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chalasani N, Wilson L, Kleiner DE, et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 48: 829-834, 2008.","DOI":"10.1016\/j.jhep.2008.01.016"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71: 793-801, 2019.","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39: 412-423, 2010.","DOI":"10.1093\/ageing\/afq034"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nishikawa H, Shiraki M, Hiramatsu A, et al. Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 46: 951-963, 2016.","DOI":"10.1111\/hepr.12774"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology 66: 2055-2065, 2017.","DOI":"10.1002\/hep.29420"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Clegg A, Hassan-Smith Z. Frailty and the endocrine system. Lancet Diabetes Endocrinol 6: 743-752, 2018.","DOI":"10.1016\/S2213-8587(18)30110-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Petta S, Ciminnisi S, Di Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 45: 510-518, 2017.","DOI":"10.1111\/apt.13889"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Izzo A, Massimino E, Riccardi G, Della Pepa G. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients 13: 183, 2021.","DOI":"10.3390\/nu13010183"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Massimino E, Izzo A, Riccardi G, Della Pepa G. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms. Cells 10: 1958, 2021.","DOI":"10.3390\/cells10081958"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol 66: 123-131, 2017.","DOI":"10.1016\/j.jhep.2016.08.019"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Kim G, Lee SE, Lee YB, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology 68: 1755-1768, 2018.","DOI":"10.1002\/hep.30049"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kitajima Y, Hyogo H, Sumida Y, et al. Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. J Gastroenterol Hepatol 28: 1507-1514, 2013.","DOI":"10.1111\/jgh.12227"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kim MJ, Cho YK, Kim EH, et al. Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography. J Cachexia Sarcopenia Muscle 15: 1942-1952, 2024.","DOI":"10.1002\/jcsm.13543"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci 65: 623-631, 2020.","DOI":"10.1007\/s10620-019-5477-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Akuta N, Kawamura Y, Watanabe C, et al. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res 49: 531-539, 2019.","DOI":"10.1111\/hepr.13304"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Takahashi H, Kessoku T, Kawanaka M, et al. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun 6: 120-132, 2022.","DOI":"10.1002\/hep4.1696"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124: 509-514, 2014.","DOI":"10.1172\/JCI70704"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Pan R, Zhang Y, Wang R, Xu Y, Ji H, Zhao Y. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. PLOS ONE 17: e0279889, 2022.","DOI":"10.1371\/journal.pone.0279889"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kitajima Y, Eguchi Y, Ishibashi E, et al. Age-related fat deposition in multifidus muscle could be a marker for nonalcoholic fatty liver disease. J Gastroenterol 45: 218-224, 2010.","DOI":"10.1007\/s00535-009-0147-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hsieh Y-C, Joo SK, Koo BK, et al. Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. Clin Gastroenterol Hepatol 21: 388-397.e10, 2023.","DOI":"10.1016\/j.cgh.2022.01.020"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123: 745-750, 2002.","DOI":"10.1053\/gast.2002.35354"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology 137: 727-729, 1980.","DOI":"10.1148\/radiology.137.3.6934563"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Yoshizumi T, Nakamura T, Yamane M, et al. Abdominal fat: standardized technique for measurement at CT. Radiology 211: 283-286, 1999.","DOI":"10.1148\/radiology.211.1.r99ap15283"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 159: 413-421, 2004.","DOI":"10.1093\/aje\/kwh058"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33: 997-1006, 2008.","DOI":"10.1139\/H08-075"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ward JH. Hierarchical grouping to optimize an objective function. J Am Stat Assoc 58: 236-244, 1963.","DOI":"10.1080\/01621459.1963.10500845"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sakamoto M, Goto Y, Nagayama A, et al. Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes. Diabetol Int 13: 117-123, 2022.","DOI":"10.1007\/s13340-021-00512-7"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Yagi S, Hirata Y, Ise T, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 9: 78, 2017.","DOI":"10.1186\/s13098-017-0275-4"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Fukuda T, Bouchi R, Terashima M, et al. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther 8: 851-861, 2017.","DOI":"10.1007\/s13300-017-0279-y"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Bouchi R, Terashima M, Sasahara Y, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol 16: 32, 2017.","DOI":"10.1186\/s12933-017-0516-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Sano M, Meguro S, Kawai T, Suzuki Y. Increased grip strength with sodium-glucose cotransporter 2. J Diabetes 8: 736-737, 2016.","DOI":"10.1111\/1753-0407.12402"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Otsuka H, Yokomizo H, Nakamura S, et al. Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice. Biochem J 479: 425-444, 2022.","DOI":"10.1042\/BCJ20210700"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Bamba R, Okamura T, Hashimoto Y, et al. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db\/db mice. J Cachexia Sarcopenia Muscle 13: 574-588, 2022.","DOI":"10.1002\/jcsm.12814"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Tanaka K, Takahashi H, Katagiri S, et al. Combined effect of canagliflozin and exercise training on high-fat diet-fed mice. Am J Physiol Endocrinol Metab 318: E492-E503, 2020.","DOI":"10.1152\/ajpendo.00401.2019"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Op den Kamp YJM, Gemmink A, de Ligt M, et al. Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism. Mol Metab 66: 101620, 2022.","DOI":"10.1016\/j.molmet.2022.101620"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ji Y, Yiorkas AM, Frau F, et al. Genome-wide and abdominal MRI data provide evidence that a genetically determined favorable adiposity phenotype Is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart disease, and hypertension. Diabetes 68: 207-219, 2019.","DOI":"10.2337\/db18-0708"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Oshida N, Shida T, Oh S, et al. Urinary levels of titin-N fragment, a skeletal muscle damage marker, are increased in subjects with nonalcoholic fatty liver disease. Sci Rep 9: 19498, 2019.","DOI":"10.1038\/s41598-019-56121-7"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Zhang W, Huang R, Wang Y, et al. Fat accumulation, liver fibrosis, and metabolic abnormalities in Chinese patients with moderate\/severe versus mild hepatic steatosis. Hepatol Commun 3: 1585-1597, 2019.","DOI":"10.1002\/hep4.1435"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Correa-de-Araujo R, Addison O, Miljkovic I, et al. Myosteatosis in the context of skeletal muscle function deficit: an interdisciplinary workshop at the National Institute on Aging. Front Physiol 11: 963, 2020.","DOI":"10.3389\/fphys.2020.00963"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Hiromine Y, Noso S, Rakugi H, et al. Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: the MUSCLES-DM study. J Diabetes Investig 13: 1881-1888, 2022.","DOI":"10.1111\/jdi.13882"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Sugimoto K, Ikegami H, Takata Y, et al. Glycemic control and insulin improve muscle mass and gait speed in type 2 diabetes: the MUSCLES-DM study. J Am Med Dir Assoc 22: 834-838.e1, 2021.","DOI":"10.1016\/j.jamda.2020.11.003"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Kawaguchi T, Takahashi H, Gerber LH. Clinics in liver disease: update on nonalcoholic steatohepatitis: sarcopenia and nonalcoholic fatty liver disease. Clin Liver Dis 27: 275-286, 2023.","DOI":"10.1016\/j.cld.2023.01.005"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Rizzo MR, Barbieri M, Fava I, et al. Sarcopenia in elderly diabetic patients: role of dipeptidyl peptidase 4 inhibitors. J Am Med Dir Assoc 17: 896-901, 2016.","DOI":"10.1016\/j.jamda.2016.04.016"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Bouchi R, Fukuda T, Takeuchi T, et al. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. Diabetes Metab Res Rev 34: 2018.","DOI":"10.1002\/dmrr.2957"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Brennan PN, Dillon JF, Tapper EB. Gamma-glutamyl transferase (\u03b3-GT) - an old dog with new tricks? Liver Int 42: 9-15, 2022.","DOI":"10.1111\/liv.15099"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Magurno M, Cassano V, Maruca F, et al. Effects of SGLT2-inhibitors on comprehensive geriatric assessment, biomarkers of oxidative stress, and platelet activation in elderly diabetic patients with heart failure with preserved ejection fraction. Int J Mol Sci 25: 8811, 2024.","DOI":"10.3390\/ijms25168811"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Minato-Inokawa S, Tsuboi-Kaji A, Honda M, et al. The different associations of serum gamma-glutamyl transferase and alanine aminotransferase with insulin secretion, \u03b2-cell function, and insulin resistance in non-obese Japanese. Sci Rep 14: 19234, 2024.","DOI":"10.1038\/s41598-024-70396-5"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/11\/64_4456-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:39:31Z","timestamp":1749271171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/11\/64_4456-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4456-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,6,1]]},"article-number":"4456-24"}}